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Abstract
Background: Successful treatments of patients with somatostatin receptor (SSTR)-overexpressing neuroendocrine
tumours (NET) comprise somatostatin-analogue lutetium-177-labelled octreotate (177Lu-TATE) treatment, also
referred to as peptide receptor radionuclide therapy (PRRT), and temozolomide (TMZ) treatment. Their combination
might result in additive effects. Using MRI and SPECT/CT, we studied tumour characteristics and therapeutic
responses after different (combined) administration schemes in a murine tumour model in order to identify the
optimal treatment schedule for PRRT plus TMZ.
Methods: We performed molecular imaging studies in mice bearing SSTR-expressing H69 (humane small cell lung
cancer) tumours after single intravenous (i.v.) administration of 30 MBq 177Lu-TATE or TMZ (oral 50 mg/kg daily for
14 days). Tumour perfusion was evaluated weekly by dynamic contrast-enhanced MRI (DCE-MRI), whereas tumour
uptake of 111In-octreotide was quantified using SPECT/CT until day 39 after treatment. Based on these results, seven
different 177Lu-octreotate and TMZ combination schemes were evaluated for therapy response, varying the order
and time interval of the two therapies and compared with single treatments.
Results: PRRT and TMZ both resulted in tumour size reduction, accompanied by significant changes in MRI
characteristics such as an enhanced tumour perfusion. Moreover, TMZ treatment also resulted in increased uptake
of the SST analogue 111In-octreotide until day 13. In the subsequent therapy study, 90 % of animals receiving 177Lu-
TATE at day 14 after TMZ treatment showed complete response, being the best anti-tumour results among groups.
Conclusions: Molecular imaging studies indicated that PRRT after TMZ treatment could induce optimal therapeutic
effects because of enhanced tumour uptake of radioactivity after TMZ, which was confirmed by therapy responses.
Therefore, clinical translation of TMZ treatment prior to PRRT might increase tumour responses in NET patients as
well.
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Background
Systemic internal radiation therapy using radiolabelled
peptides, specifically targeting receptors overexpressed
on tumour cells, is an attractive cancer treatment. A
high absorbed radiation dose is being delivered to tu-
mours with a tolerable toxicity in normal non-targeted
tissues. This so-called peptide receptor radionuclide
therapy (PRRT) has been shown to be a most effective
treatment option for patients with SSTR-expressing neu-
roendocrine tumours (NETs) [1–3].
Most NETs are slowly proliferating tumours, making
them relatively resistant to most chemotherapeutics. In
more than 50 % of the patients, NETs are diagnosed at a
relatively late stage, often with metastatic spread [4],
which leaves little chance for curative surgery. Then,
PRRT with radiolabelled SST analogues appeared to be
an attractive cancer treatment. A high absorbed dose is
being delivered to tumours with a tolerable toxicity in
normal non-targeted tissues [1–3]. Radiolabelled SST an-
alogues, such as 111In-DTPA-octreotide (111In-octreo-
tide) or 177Lu-DOTA,Tyr3-octreotate (177Lu-TATE),
show a high binding affinity for the somatostatin recep-
tor type 2 (SSTR2), which is overexpressed on the vast
majority of NETs [5].
PRRT has proven to be an effective therapy in most
patients with NETs [1, 6]. Nevertheless, despite the im-
provement of progression-free survival and quality of
life, complete remissions after PRRT are still rare. A
combination of PRRT with radio-sensitizing chemother-
apeutics, such as capecitabine (5-fluorouracil) or temo-
zolomide (TMZ), might induce synergistic effects [7–9].
Currently, phase II clinical trials combining PRRT, using
177Lu-TATE and capecitabine or both capecitabine and
TMZ, are ongoing. The first analyses showed promising
results [8, 10].
When PRRT with chemotherapeutics are being com-
bined, also potential negative interactions between the
two therapies should be taken into consideration.
Chemotherapy might affect the SSTR2 expression on
tumour cells, on which PRRT depends for targeting of
radionuclides, for example [11, 12]. Moreover, tumour
vasculature might be affected by chemotherapy whereas
efficient/adequate tumour perfusion is required for local
delivery of 177Lu-TATE [13]. To obtain an optimal thera-
peutic scheme for the combination of PRRT and TMZ,
information on the aforementioned tumour characteris-
tics during treatment is required, which was the aim of
this pre-clinical study using an H69-tumour-bearing
mouse model. Tumour perfusion was monitored by dy-
namic contrast-enhanced (DCE)-MRI and SSTR expres-
sion by 111In-octreotide SPECT. The results from these
imaging studies were applied in the design of different
therapeutic schemes to stratify maximum therapeutic ef-
ficacy using TMZ and PRRT.
Methods
Experimental setup
We have started a pilot study in which H69 tumour-
bearing mice were treated with increasing amounts of
177Lu-TATE to determine which dose resulted in clear
tumour responses but without complete cure to allow
detection of additional effects during combination ther-
apy. Three groups (n = 7) of H69-tumour-bearing mice
were treated with 10, 20 or 30 MBq 177Lu-TATE and
compared with untreated control animals. Monitoring of
body weight and tumour size was performed until day
28 after the start of treatment.
For TMZ treatment, different dosing schedules have
been reported, including a total administered dose of
>1000 mg/kg [14] or the administration of one or
more cycles during 5 days, in which a dose of 50 or
120 mg/kg/day was administered [15, 16]. Since we
planned to administer only one cycle, we used a dose
of 50 mg/kg/day for 2 weeks, to study the effects of
TMZ treatment in the H69 model, supplemented with
investigations into combination of PRRT and TMZ. In
this study, the earlier determined optimal dose of
30 MBq 177Lu-TATE was used.
Imaging studies to determine tumour characteristics during
PRRT or TMZ treatment
Three groups of mice were included in this imaging
study (Table 1). The PRRT group received a single dose
of 50 MBq 177Lu-TATE on day 1, and the TMZ group
was treated with 50 mg/kg TMZ administered orally for
2 weeks, starting at day 0. The control group received
saline. The timeline for these studies is shown in Fig. 1a.
PRRT group Mice (n = 4) received a baseline DCE-MRI
scan 1 day prior to administration of 50 MBq 177Lu-
TATE. During follow-up of the therapy, MRI scans were
acquired on days 4, 7, 11, 15, 20 and 28. Moreover, a
SPECT/CT scan to determine the tumour uptake of
177Lu-TATE was performed 24 h after administration.
TMZ group Mice (n = 7) received one baseline DCE-
MRI scan 2 days prior start of TMZ treatment, which
was repeated once weekly during and after TMZ treat-
ment until day 28. To determine the level of radiopep-
tides uptake, 111In-octreotide SPECT/CT scanning was
performed 1 day prior start of TMZ treatment and re-
peated once weekly for 6 weeks during and after TMZ.
At day 1 (before TMZ), day 14 (after TMZ) and day 28,
when tumours showed maximal response, three mice
where sacrificed to collect the H69 xenograft to deter-
mine the level of SSTR expression by in vitro autoradi-
ography using 111In-octreotide.
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Control group Non-treated mice (n = 3) received four
DCE-MRI scans: at days 1, 5 and 12.
Combination therapy of PRRT and TMZ
Seven groups of mice were included to compare H69 re-
sponses after different combination treatment schedules,
including a placebo control group (receiving oraplus so-
lution without TMZ p.o. once daily.) (Table 2). Uptake
of 177Lu-TATE was quantified in three to six tumours of
each group after PRRT by SPECT imaging. The timeline
for these studies is shown in Fig. 1b.
Tumour cell line
The SSTR2-expressing human small cell lung cancer cell
line H69 was obtained from ECACC (Salisbury, UK) and
grown in RPMI medium (Gibco, Invitrogen Corp.,
Table 1 Treatment and imaging for each group
Group Number of mice Treatment Imaging
177Lu-TATE 4 50 MBq 177Lu-TATE i.v. 6 × MRI, 1 × SPECT/CT
TMZ 7 TMZ 50 mg/kg p.o. for 14 days 7 × MRI, 7 × SPECT/CT
Control 3 Saline 3 × MRI
177Lu-TATE lutetium-177-labelled octreotate, TMZ temozolomide
-21     0   7   14        21  28       35  42
Day-21 0 14 28 130
a
b
Fig. 1 Timeline for the imaging study (a) and for the combination therapy studies (b)
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Breda, The Netherlands) supplemented with 10 % heat-
inactivated foetal bovine serum.
Animals and tumour model
All animal experiments have been conducted with prior
approval of the animal ethics committee of our institu-
tion and performed in accordance with Dutch laws.
Male NMRI nu/nu mice (body weight ~33 g) were ob-
tained from Harlan (Heerlen, the Netherlands). One
week after arrival, at the age of 5–7 weeks, mice were in-
oculated subcutaneously with 107 H69 cells in 0.2-ml
HBSS. For all experiments, animals were randomized
into matching treatment groups regarding tumour size
at the start of treatment 4 weeks after tumour inocula-
tion. Randomized treatment groups were created by
matched pairs randomization. Three times a week, mice
were weighed and length and width of the tumour were
measured using a calliper by a person blinded for the
treatment. Tumour volume was calculated using the for-
mula 0.5(length × width)1.5 adapted from the SWOG cri-
teria. Mice were euthanized when >10 % loss of body
weight (BW) since start of the experiment was observed
or when tumour volume exceeded 1800 mm3.
Chemotherapeutics
Temozolomide was obtained from Sun Pharmaceutical
Industries Europe B.V. (Hoofddorp, The Netherlands).
In the pilot study, TMZ was dissolved as 8 mg/ml 50 %
glucose jelly and 200 μl was administered orally. For the
imaging and final therapy studies, a 8 mg/ml solution
TMZ was prepared in Oraplus (Paddock laboratories,
Inc. Minneapolis USA) and 200 μl aliquots were admin-
istered by oral gavage 5 days a week for 2 weeks result-
ing in a dose of 50 mg/kg/day TMZ.
Radionuclides and peptides
DOTA,Tyr3-octreotate was obtained from Mallinckrodt,
St Louis, MO, and 177LuCl3 was obtained from NRG
Petten, The Netherlands. 177Lu-TATE was prepared as
described previously [17] with a specific activity of
100 MBq/2.75 μg peptide, and 10, 20, 30 or 50 MBq was
injected intravenously (i.v.) in a volume of 200 μl via the
tail vein. Labelling of 111In-DTPA-octreotide (OctreoS-
can, Covidien, Petten, The Netherlands) was performed
as described at a specific activity of 30 MBq/1.0 μg
DTPA-octreotide [17].
SPECT/CT
During scanning experiments, 2.0 % isoflurane/O2 gas
anaesthesia was applied at 0.5 ml/min. Twenty-four
hours after injection of 177Lu-TATE or 111In-octreotide,
helical SPECT/CT of the tumour region was performed
with a four-headed NanoSPECT/CT system (BioScan,
Washington DC USA) with nine pinhole mice collima-
tors (diameter 1.4 mm) per head. The scans were ob-
tained using 24 projections of 120 s per projection and a
quality factor of 0.7. SPECT scans were reconstructed it-
eratively on a 256 × 256 matrix, using HiSPECT NG
software (Scivis, GmbH Göttingen Germany) and or-
dered subset expectation maximization (OSEM). The
total amount of radioactivity (MBq) in the tumour was
quantified by 3D quantification using InVivoScope soft-
ware (IVS, Bioscan, Washington DC USA). To achieve
accurate quantification, the camera was calibrated by
scanning a 20-mL polypropylene tube phantom filled
with a known amount of 177Lu or 111In radioactivity.
During scanning, body temperature of the mice was
maintained using a heated bed.
MRI
Imaging was performed on a pre-clinical 7.0T scanner
(Discovery MR901, Agilent technologies/GE Healthcare)
with the standard imaging gradient set (300 mT/m, slew
rate of 1000 mT/m/ms—rise time = 300 μs). A 150-mm
transmit coil and four-channel surface coil (5 cm FOV)
were used to acquire all images.
DCE-MRI data were acquired following a bolus i.v.
injection of Gadobutrol (Gadovist; Bayer Healthcare,
Germany). The acquisition parameters used were
repetition time (TR) = 10 ms, echo time (TE) = 2 ms,
flip angle 12°, matrix size = 116 × 116 and slice
thickness = 0.8 mm with a total imaging volume of
Table 2 Treatment schedule and number of mice for each group
Group Treatment Number of mice
177Lu-TATE TMZ
Control – Placebo 5
1: PRRT single 30 MBq day 0 Placebo 8
2: PRRT double 30 MBq day 0 Placebo 8
3: TMZ – 50 mg/kg for 14 days from day 0 8
4: PRRT + TMZ at day 14 30 MBq day 0 50 mg/kg for 14 days from day 14 8
5: PRRT + TMZ 30 MBq day 0 50 mg/kg for 14 days from day 0 8
6: TMZ + PRRT at day 14 30 MBq day 14 50 mg/kg for 14 days from day 0 10
177Lu-TATE lutetium-177-labelled octreotate, TMZ temozolomide, PRRT peptide receptor radionuclide therapy
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50 × 50 × 32 mm3 (x, y, z). Four k-space segments
were acquired using a segmented readout sequence
called TRICKS [18]. This resulted in a temporal
resolution of 4.7 s. Before contrast administration,
four to five time points were acquired to obtain the
baseline signal intensity. Prior to acquiring the DCE-
MRI image series, a saturation recovery T1 map was
acquired using a spin echo sequence with varying
TRs, settings: TE = 8 ms, TR = 200, 400, 800 and
1600 ms. T2 maps were also acquired with a spin
echo sequence varying TE, settings: TR = 1200 ms,
TE = 8, 16, 25 and 35 ms. All mapping images were
acquired with slice thickness 0.8 mm, 5 cm FOV and
256 × 256 matrix.
Image analysis
Analysis of the SPECT data: the concentration of activity
in the tumours was calculated by dividing the total
amount of activity in the tumour determined by 3D
quantification with HiSPECT NG software through
the 3D tumour volume determined during this
quantification.
For analysis of the DCE-MRI data, we used two
methods: semi-quantitative and quantitative analysis. All
calculations were performed using Matlab (Mathworks
co.). In semi-quantitative analysis, the signal-intensity
time curves were used to determine the time to peak
(TTP), maximum signal enhancement (Smax) and the
area under the curve (AUC) for the total curve and also
for the first 60 s (AUC60). The AUC and AUC60 were
calculated using a triangulation algorithm. Furthermore,
the wash-in was calculated as a linear slope from the
first point before contrast enhancement to the first max-
imum. The wash-out was calculated from the slope of
the first maximum to the measurement at 60 s after in-
jection. The wash-out curve was not necessarily linear in
shape, but using this method, we were able to discrimin-
ate the wide variety in wash-out kinetics. In order to cal-
culate quantitative parameters from the DCE-MRI data,
the signal-intensity time curves were converted to
contrast-concentration time curves using a T1-map cali-
bration. A pharmacokinetic compartment model could
be fitted to these contrast-concentration time curves.
Quantitative analysis consisted of calculation of ktrans
and kep, calculated according to Tofts perfusion model
[19]. A population-based average arterial input function
(AIF) obtained from Weidensteiner [20] was used for
consistency in the results. For the response to therapy,
comparison of the tumour perfusion parameters was
performed; regions of interest were drawn around the
tumours, and mean parameter values were calculated.
ktrans is the calculated rate constant for the passage of
contrast agent into the tissue. The rate constant kep is
the reflux of contrast agent from tissue back to the
blood. The results presented show the ktrans which per-
formed slightly better than the kep in this model due to
the limited amount of wash-out in the 10-min scantime.
In vitro autoradiography on tumours treated with TMZ
during the imaging study
Sections of 10 μm were sliced from frozen tumours
(Cryo-Star HM 560 M; Microm, Walldorf, Germany),
mounted on Superfrost plus slides (Menzel, Braun-
schweig, Germany) and incubated with 10−9M 111In-
octreotide with and without an excess (10−6M) of un-
labelled octreotide. Adjacent sections were stained with
haematoxylin/eosin. Tumour sections were exposed to
SR phosphor imaging screens (Packard Instruments Co.,
Meriden, USA) in X-ray cassettes. After 48-h exposure,
screens were read by a Cyclone phosphor imager and
analysed using OptiQuant 03.00 (Perkin Elmer, Gro-
ningen, The Netherlands). Autoradiogram quantification
was expressed in density light units (DLU) per square
millimetre.
Statistics
Prism software version 5.0 (Graph Pad) was used to ana-
lyse tumour growth and determine statistical significance
between groups. One-way ANOVA was used for statis-
tical analysis of tumour uptake, and results are given as




All three 177Lu-TATE groups showed delay of tumour
growth compared with the control group (Fig. 2). As ex-
pected, the most significant tumour growth suppression
was found in the 30 MBq group, although complete re-
sponse was not reached in any mouse.



















Fig. 2 Dose-finding study: H69 tumour volume as a percentage
compared with day 0 (±SD) after treatment with different amounts of
177Lu-TATE, seven mice/group
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Imaging studies
Effect of single-agent treatment on tumour growth
Treatment with either 177Lu-TATE or TMZ resulted
in transient reduction in tumour size/volume, con-
firming previous results. However, the kinetics of the
tumour response after the two treatments differed
(Fig. 3a).
The average 177Lu uptake in the four tumours in the
PRRT group was 1.7 ± 0.1 kBq/mm3 (3.4 ± 0.2 %IA/g) at
24 h after administration of 50 MBq 177Lu-TATE. Max-
imum reduction of tumour volume was reached at ~day
14, after which the tumours increased in size again.
After an average of 43 days, euthanasia was needed be-
cause the maximal allowed tumour size (1800 mm3) was
reached.
In mice treated with TMZ, the tumour volumes in-
creased until day 9 reaching maximum tumour sizes,
after which decrease of tumour sizes was observed. At
day 51, at the end of the imaging study, the average
tumour volume increased again; however, at that time,
none of the tumours exceeded a volume of 1800 mm3.
Tumour perfusion during 177Lu-TATE or TMZ treatment
Tumours subjected to TMZ and 177Lu-TATE initially
showed a fast decrease in ktrans, reaching minimum
values at day 4 ((2.2 ± 2) × 10−3 min−1 for 177Lu-TATE)
or day 5 ((2.0 ± 2) × 10−3 min−1 for TMZ). When tumour
size decreased, an increase in ktrans was measured. The
local maximum in ktrans values was reached approxi-
mately 2 weeks after (start of ) treatment. Tumours in
the group receiving TMZ showed the highest ktrans
values at day 13 ((11 ± 1) × 10−3 min−1); the 177Lu-TATE
group’s maximum ktrans value was reached at day 15
((5.8 ± 2) × 10−3 min−1). During further follow-up, the
ktrans values decreased again in both the TMZ and
177Lu-TATE group.
SSTR2 expression and uptake of 111In-octreotide before and
after TMZ treatment
In vitro autoradiography results showed no difference in
SSTR2 expression of H69 xenografts before (day 0) or
after (day 15 and day 28) TMZ treatment (Fig. 4a). Yet,
SPECT imaging showed that at day 0 (average tumour
b



































Fig. 3 Effect on H69 tumour volume (a) and tumour perfusion (b) of single-agent treatment. a Tumour volume as a percentage compared to day
0 ± SD. b Average intra-tumoural ktrans was calculated, and the presented data show the average across tumours with the SD. The control group
(n = 3) (black line) received saline, the PRRT group (n = 4) was treated with 50 MBq 177Lu-TATE (blue line) on day 0, and the temozolomide (TMZ)
group (n = 7) (red line) was treated for 14 days with orally administered TMZ at a dose of 50 mg/kg/day
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volume 456 mm3), the average radioactivity after injec-
tion of 111In-octreotide was 0.4 ± 0.2 kBq/mm3 (1.5 ±
0.4 %IA/g) H69 xenograft, while after 14 days of TMZ
treatment, this was increased until 0.9 ± 0.3 kBq/mm3
(2.9 ± 0.9 %IA/g) (average tumour volume 442 mm3).
When the administration of TMZ was discontinued, the
111In-H69 uptake dropped again to 0.5 ± 0.2 kBq/mm3
(1.7 ± 0.5 %IA/g) at day 18 and 0.5 ± 0.2 kBq/mm3 (1,5 ±
0.5 %IA/g) at day 27, further declining until day 39
(Fig. 4b).
Therapy study
Responses to the different treatment schedules
As expected, all mice in the control group had to be eu-
thanized due to excessive tumour growth. This was also
true for the mice in the single-treatment groups with
177Lu-TATE (groups 1 and 2) or TMZ (group 3), albeit
with a significant delay of 20–50 days (Fig. 5b). The
median survival time (MST) to reach the maximum
tumour size of 1800 mm3 was 32 days for the mice in
the control group versus 53 days for the single 177Lu-
TATE group 1 and 74 days for the double 177Lu-TATE
group 2. The single TMZ group 3 reached an extended
MST of 81 days.
In all three groups treated with a combination of
177Lu-TATE and TMZ, an additive effect of the two
treatments was determined. Since in several mice
complete tumour response was reached, MST could not
be determined. Regarding survival, the difference be-
tween the best performing single-therapy group 3
(TMZ) and group 4 (TMZ 14 days after 177Lu-TATE)
was significant (p = 0.046), whereas the other combin-
ation groups performed even better. Thus, the applied
treatment schedules in these three groups had a striking
impact on tumour response. In group 4, still 57 % of tu-
mours reached a volume of 1800 mm3 before the end of
the study at day 123. When 177Lu-TATE and TMZ were
combined from the start (group 5), only 25 % of tu-
mours reached this maximum size. By far, the best result
was obtained in group 6 with 177Lu-TATE administered
after 14 days TMZ treatment. Only one tumour (10 %)
escaped from treatment, whereas the other tumours
showed complete response.
Tumour uptake of 177Lu-TATE
The uptake of 177Lu-TATE in H69 tumours was quanti-
fied 24 h after administration of 30 MBq 177Lu-TATE
based on SPECT/CT imaging. As reference, the average
177Lu-tumour uptake was 1.7 ± 0.2 kBq/mm3 without
previous treatment. When after 14 days a second dose of
177Lu-TATE was given, a comparable 177Lu-tumour con-
centration of 1.7 ± 0.1 kBq/mm3 (5.6 ± 0.3 %IA/g) was
found. However, in mice receiving 177Lu-TATE on day
14 after initial TMZ for 14 days, a significantly higher
uptake of 2.2 ± 0.5 kBq/mm3 (7.5 ± 1.5 %) was deter-
mined (p = 0.013) (Fig. 5c).
Discussion
Despite the fact that significant tumour response rates
have been reported after treatment of NET patients with
177Lu-TATE or [90Y-DOTA]-D-Phe1-Tyr3-octreotide
(90Y-DOTATOC) [21, 22], complete responses are still
rare, urging for improvements of PPRT protocols. TMZ
is currently being applied in combination with radiother-
apy for treatment of glioblastoma patients [23]. TMZ (+
cap) is also effective in NET patients [24, 25]. Therefore,
we examined in mice if this alkylating agent offered syn-
ergistic effects when combined with 177Lu-TATE PRRT.
In this pre-clinical study, we aimed to elucidate the
most effective treatment schedule of the TMZ and PRRT
combination. We applied a TMZ dose of 50 mg/kg daily












































Fig. 4 Graphs showing SSTR expression of H69 tumours treated with
temozolomide (TMZ) and tumour uptake of 111In-octreotide. a
Quantification of somatostatin receptor (SSTR) density in frozen sections
of H69 tumours as determined by 111In-octreotide in vitro
autoradiography. The amount of radioactivity is expressed in density
light units (DLU) per square millimetre. SSTR expression was quantified at
day 0, day 14 (1 day after TMZ treatment), and day 28 when tumours
reached a minimal volume after TMZ treatment. Three tumours/day
were examined. b Based on SPECT images, the average tumour
concentration of 111In-octreotide was determined 24 h after
administration. Mice were treated with TMZ from day 0 until day 13
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our H69 model not resulting in complete responses. The
same was true for a dose of 30 MBq 177Lu-TATE leading
to a significant delay of H69-tumour size increase.
The human small cell lung cancer (SCLC) H69 cell
line, used in our studies, expresses SSTR2 in high dens-
ities. As a subtype of NETs, SCLC accounts for about
20 % of all lung cancers [26] and shows a 5-year survival
rate of only 20 % [26]. For this type of cancer, there is a
clear need to find therapeutic methods resulting in bet-
ter survival. Several chemotherapeutics, including TMZ,
are being used to treat SCLC [27], making the H69 cell
line a suitable model for pre-clinical in vivo PRRT re-
search using radiolabelled SST analogues [28]. To study
dosimetry and tumour response, Schmitt et al. applied
several activity doses of 177Lu-TATE for PRRT of H69
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Fig. 5 Graphs showing for each treatment group a average H69 tumour volume, b percentage of animals with tumours <1800 mm3, and c average
tumour radioactivity at 24 h after administration of 177Lu-TATE A. Average tumour volume as a percentage compared with day 0. Tumours >1800 were
taken out of the follow-up, which influenced the average tumour volume shown in the curves. The control group was treated with placebo, 30 MBq
177Lu-TATE was i.v. administered at day 0 to mice in groups 1, 4 and 5, at day 14 for group 6 and both at day 0 and day 14 for group 2. TMZ was
administered orally once daily for 14 days at a dose of 50 mg/kg from day 0 to mice in groups 3, 4 and 6, starting at day 14 for group 5. Eight to ten
mice/group. c Average tumour radioactivity: orange bar: groups 1, 2 (first dose), 4, 5; red bar: group 6; green bar: group 2 (second dose). Numbers,
respectively, 14, 6 and 6 mice/group
Bison et al. EJNMMI Research  (2015) 5:62 Page 8 of 11
showed a significantly higher uptake of radioactivity
compared with all normal organs [28]. In a therapy
study, using substantially larger tumours than in our
study (respectively, 1000 and 2000 mm3 at day 0), in-
creasing growth delays using doses of 45, 60 and
120 MBq or two fractions of 45 MBq 177Lu-TATE
were found [29].
In the clinical trials in which PRRT was combined
with capecitabine and TMZ, the focus mainly has been
on the radio-sensitizing effects of the chemotherapeutics
[8, 30], not considering other effects these agents might
have on tumour characteristics. In our opinion, the po-
tential influence of chemotherapeutics on tumour perfu-
sion and SSTR2 expression is of major importance as
well, to determine an optimal scheme for the combin-
ation of PRRT with chemotherapeutics.
In this study, we measured an increase of H69-tumour
perfusion after TMZ treatment. The highest values after
14 days of TMZ treatment coincide with a peak in the
uptake of radiolabelled octreotide. The latter observation
was confirmed during therapy, as 177Lu-uptake in H69
tumours after 177Lu-TATE administration was signifi-
cantly higher when mice were pre-treated for 14 days
with TMZ. This was not the case when pre-treatment
consisted of an additional dose of 177Lu-TATE.
This increased tumour uptake/retention of radioactiv-
ity after TMZ treatment can be explained by different
phenomena. A relation between tumour volume and
concentration of radioactivity has been described, indi-
cating an increased concentration of radioactivity in
smaller tumours [28]. In our studies, however, the aver-
age tumour size was in the same range at day 0 and at
day 13, respectively, a mean tumour volume of 456 ±
122 versus 442 ± 66 mm3, demonstrating that the peak
of radioactivity uptake at day 13 was not influenced by
tumour volume. At later time points, when tumour sizes
continued to decrease as a result of TMZ treatment, also
the concentration of 111In-octreotide decreased.
An increased level of SSTR2 expression might also ex-
plain the peak of radiopeptide uptake after 14 days of TMZ.
Using in vitro studies, Fueger et al. showed increased
SSTR2 expression in pancreatic tumour cells 4 days after
exposure to several chemotherapeutics, not including TMZ
[11, 12]. This phenomenon could not explain our findings
in the current study, however, as we found no differences
in SSTR2 expression prior to or after TMZ treatment,
when in vivo H69-uptake of 111In-octreotide peaked.
Therefore, increased tumour perfusion caused by TMZ
treatment offers the best explanation for the raised levels
of 111In and 177Lu tumour uptake, as was explored and
confirmed by application of measurement of perfusion pa-
rameters by DCE-MRI.
In multiple studies, TMZ, when administered in a
metronomic (repetitive, low dose) schedule, has been
demonstrated to have anti-angiogenic effects that may re-
sult in normalized tumour vasculature depending on the
administered TMZ dose [31, 32]. Therefore, direct or in-
direct anti-angiogenic effect of chemotherapeutics can im-
prove tumour perfusion and reduce the interstitial
pressure [33], enabling enhanced delivery to the tumour
of therapeutic compounds, including radiolabelled pep-
tides. Our measurements with DCE-MRI support the sug-
gestion that there is an important relationship between
functional vasculature and radiopeptide uptake [34].
Considering the anti-tumour response, a small but not
significant (p = 0.28) difference was found between group
5 (concurrent 177Lu-TATE and TMZ) and group 6
(177Lu-TATE after 14 days TMZ treatment) regarding
CR, with 75 versus 90 % CR, respectively. However,
when we compare group 6 with group 4 (the group in
which 177Lu-TATE was administered at day 1 and TMZ
treatment started at day 14), a striking and significant
difference (p = 0.046) between those groups was found,
in agreement with the fact that TMZ potentiates the ef-
fect of 177Lu-TATE.
Therefore, the optimal response found in the group re-
ceiving 177Lu-TATE after TMZ treatment might be
based on a combination of factors:
1. Increased uptake of 177Lu-TATE because of
enhanced perfusion resulting in a higher absorbed
tumour radiation dose and therefore an increased
anti-tumour response [35].
2. Increased radiosensitivity induced by TMZ. The
cytotoxicity of TMZ is primarily due to alkylation at
the O6 position of guanine combined with an
additional alkylation at the N7 position. TMZ has
been reported to act synergistically with radiation
therapy, as alkylated guanine has been reported to
be radio-sensitizing [9], as was shown in multiple
types of cancer cells [9, 36]. As the half-life of 177Lu
is 6.7 days [28], also the group receiving 177Lu-TATE
at the same day that TMZ treatment was started
might have had some benefit from the radio-
sensitizing effects of TMZ.
3. Increased oxygenation might have contributed to
improved therapeutic responses, as was
demonstrated for radiation therapy [37]. After beta-
particle radiation, DNA damage occurs as a result of
the creation of free oxygen radicals [38], so the effect
of 177Lu-TATE treatment might be enhanced when
tumour oxygenation is improved. The mice receiving
177Lu-TATE 14 days prior to TMZ treatment did
not have this benefit.
Despite the fact that our model has been carefully
chosen, it has important differences from the patient
situation. Differences in, e.g. tumour growth rate might
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influence the outcome of these studies in a clinical set-
ting. Therefore, the translational value of our findings
into the clinic remains to be proven.
During our combination therapy study, no signs of
severe toxicity like, e.g. remarkable loss of weight have
occurred. Nevertheless, during PRRT as well as
chemotherapy, toxicity is an aspect of great concern. In
a clinical study, a treatment scheme in which PRRT was
combined with capacetabine and TMZ has been shown
to be safe [8]. Considering increased uptake of radionu-
clides after TMZ treatment, in our opinion, this is likely
to be solely applicable to the tumour because of its im-
mature vasculature. However, further investigation on
toxicity and uptake of radionuclides by the normal or-
gans is warranted.
Conclusions
The use of SPECT/CT and MRI enabled us to optimize
a treatment schedule for the combination of PRRT and
TMZ in H69-xenografted nude mice. Increased perfu-
sion following TMZ pre-treatment, determined by DCE-
MRI, coinciding with increased uptake of 177Lu-TATE as
proven by SPECT/CT, was reflected by the induced
therapeutic effects we observed.
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